Literature DB >> 1877102

Role of lymphadenectomy in renal cell carcinoma.

D P Wood1.   

Abstract

A hilar or limited lymph node dissection will not remove the primary lymphatic drainage area of either kidney. For a lymphadenectomy to have a therapeutic benefit, an extended dissection is required, particularly for right-sided tumors. An extended lymphadenectomy may not be justified in all patients with renal cell carcinoma, particularly those with small tumors (who rarely have lymphatic disease) or grossly positive nodes (who have a high risk of existing distant metastases). For some patients with T3 or V+ tumors and palpably normal retroperitoneal nodes, an extended nodal dissection may resect microscopically involved nodes and result in an improved survival rate. This hypothesis will not be tested appropriately until a randomized controlled study is performed.

Entities:  

Mesh:

Year:  1991        PMID: 1877102

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  5 in total

Review 1.  The role of lymphadenectomy in the management of renal cell carcinoma.

Authors:  Glen W Barrisford; Boris Gershman; Michael L Blute
Journal:  World J Urol       Date:  2014-04-11       Impact factor: 4.226

2.  Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma.

Authors:  Stephen J Freedland; Jean B Dekernion
Journal:  Rev Urol       Date:  2003

Review 3.  The role of lymph node dissection in renal cell carcinoma.

Authors:  Brian F Chapin; Scott E Delacroix; Christopher G Wood
Journal:  Int J Clin Oncol       Date:  2011-04-28       Impact factor: 3.402

4.  A comparison of two different incisional approaches in the surgical treatment of renal cell carcinomas.

Authors:  M Abdurrahim Imamoğlu; Hasan Bakirtaş; Levent Sağnak; Can Tuygun; Hamit Ersoy
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 5.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.